“The endocannabinoid (eCB) system plays an important role in the control of mood, and its dysregulation has been implicated in several psychiatric disorders.
Targeting the eCB system appears to represent an attractive and novel approach to the treatment of depression and other mood disorders.
…the review provides discussion on compounds and drugs that target this system and might prove to be successful for the treatment of mood-related psychiatric disorders.
The discovery of increasingly selective modulators of CB receptors should enable the identification of optimal therapeutic strategies.
It should also maximize the likelihood of developing safe and effective treatments for debilitating psychiatric disorders.”